New treatments for levodopa-induced motor complications-Reference-Cited by-同舟云学术

New treatments for levodopa-induced motor complications

Published:2015-08-21 Issue:11 Volume:30 Page:1451-1460
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Rascol Olivier¹²,Perez-Lloret Santiago³⁴,Ferreira Joaquim J⁵⁶

Affiliation:

1. Department of Clinical Pharmacology and Neurosciences; University Hospital and University of Toulouse 3; France

2. INSERM CIC1436 and UMR825; Toulouse France

3. Laboratory of Epidemiology and Experimental Pharmacology, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA)

4. National Scientific and Technological Research Council (CONICET); Buenos Aires Argentina

5. Clinical Pharmacology Unit; Instituto de Medicina Molecular; Lisbon Portugal

6. Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon; Portugal

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.26362/fullpdf

Reference67 articles.

1. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism;Birkmayer;Parkinsonism Relat Disord,1998

2. Levodopa and the progression of Parkinson's disease;Fahn;N Engl J Med,2004

3. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature;Ahlskog;Mov Disord,2001

4. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease;Fox;Mov Disord,2011

5. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa;Hauser;Mov Disord,2007

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model;Neuropharmacology;2024-10

2. Istradefylline Safety Profiles: Examination of Individual Case Safety Reports in the FDA Adverse Event Reporting System (FAERS) Database;2024-04-02

3. Medical professional's viewpoint and clinical adoption;Handbook of Digital Technologies in Movement Disorders;2024

4. Management of OFF condition in Parkinson disease;Mental Health Clinician;2023-12-01

5. Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study;Journal of Movement Disorders;2023-05-31